This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clovis Oncology 관리

관리 기준 확인 3/4

Clovis Oncology's CEO is Patrick Mahaffy, appointed in Apr 2009, he has a tenure of 14.25 years. He directly owns 0.67% of the company’s shares, worth €14.56K. The average tenure of the management team and the board of directors is 7.4 years and 14.3 years respectively.`

주요 정보

Patrick Mahaffy

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	14.3yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	7.4yrs
이사회 평균 재임 기간	14.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Patrick Mahaffy 의 보수는 Clovis Oncology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2022	n/a	n/a	-US$252m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$3m	US$739k	-US$265m
Sep 30 2021	n/a	n/a	-US$299m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$3m	US$721k	-US$369m
Sep 30 2020	n/a	n/a	-US$370m
Jun 30 2020	n/a	n/a	-US$385m
Mar 31 2020	n/a	n/a	-US$413m
Dec 31 2019	US$7m	US$719k	-US$400m
Sep 30 2019	n/a	n/a	-US$400m
Jun 30 2019	n/a	n/a	-US$396m
Mar 31 2019	n/a	n/a	-US$377m
Dec 31 2018	US$6m	US$689k	-US$368m
Sep 30 2018	n/a	n/a	-US$321m
Jun 30 2018	n/a	n/a	-US$291m
Mar 31 2018	n/a	n/a	-US$366m
Dec 31 2017	US$9m	US$636k	-US$346m
Sep 30 2017	n/a	n/a	-US$365m
Jun 30 2017	n/a	n/a	-US$370m
Mar 31 2017	n/a	n/a	-US$324m
Dec 31 2016	US$789k	US$224k	-US$349m

보상 대 시장: Insufficient data to establish whether Patrick's total compensation is reasonable compared to companies of similar size in the German market.

보상과 수익: Patrick's compensation has been consistent with company performance over the past year.

CEO

Patrick Mahaffy (60 yo)

14.3yrs

테뉴어

US$2,639,083

보상

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

리더십 팀

이름	위치	테뉴어	보상	소유권
Patrick Mahaffy	Co-Founder	14.3yrs	US$2.64m	0.67% $ 14.6k
Daniel Muehl	Executive VP & CFO	7.3yrs	US$1.19m	0.072% $ 1.6k
Paul Gross	Executive VP	7.5yrs	US$1.20m	0.068% $ 1.5k
Lindsey Rolfe	Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer	7.9yrs	US$1.24m	0.078% $ 1.7k
Thomas Harding	Executive VP & Chief Scientific Officer	3.8yrs	데이터 없음	데이터 없음
Ann Bozeman	Executive Vice President of Human Resources	6.8yrs	데이터 없음	데이터 없음

7.4yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: C6O's management team is seasoned and experienced (7.4 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Patrick Mahaffy	Co-Founder	14.3yrs	US$2.64m	0.67% $ 14.6k
Paul Klingenstein	Independent Director	14.3yrs	US$260.00k	0.041% $ 889.9
Brian Atwood	Independent Director	14.5yrs	US$270.00k	0.040% $ 875.1
Edward McKinley	Independent Director	14.5yrs	US$270.00k	0.17% $ 3.8k
James Blair	Independent Director	14.5yrs	US$270.00k	0.044% $ 953.2
Ginger Graham	Independent Chairman	10.5yrs	US$287.50k	0% $ 0
Thorlef Spickschen	Independent Director	14.5yrs	US$257.50k	0.040% $ 872.7
Ronit Simantov	Director	2yrs	US$375.21k	데이터 없음
Keith Flaherty	Independent Director	10.5yrs	US$259.58k	0% $ 0
Richard Fair	Independent Director	4.8yrs	US$257.50k	0% $ 0
Robert Azelby	Independent Director	4.8yrs	US$255.00k	0% $ 0

14.3yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: C6O's board of directors are seasoned and experienced ( 14.3 years average tenure).

This company listing is no longer active

Clovis Oncology 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue beats expectations

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €7.51

New 90-day high: €4.99

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.84

Clovis Oncology, Inc. to Report Q1, 2020 Results on May 05, 2020

Clovis Oncology, Inc. Presents Highlight Breadth and Potential of Clovis Oncology Products and Pipeline At ESMO Virtual Congress 2020

First half earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령